Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 82%
filed 2026-09-22
Item 8.01
Elmet Group entered into a long-term tungsten concentrate offtake agreement with Tungsten West PLC covering production from the Hemerdon Mine, expected to deliver over 1,000 metric tonnes per year (representing more than $230 million annually at current prices). This material strategic supply contract advances the Company's critical materials supply chain objectives and complements a $450 million U.S. Department of War investment announced September 14, 2026.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-22
EX-99.1
ZenaTech's ZenaDrone subsidiary received Specific Operations Risk Assessment (SORA) approval from the Irish Aviation Authority to conduct large-scale precision agriculture drone services in Ireland, enabling commercial operations in a new European geographic market and supporting the company's DaaS expansion strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-22
EX-99.3
ZenaTech was selected as a qualified supplier under Canada's Defence Drone Initiative (DDI) Marketplace, pre-qualifying the company to compete for future defense and security drone contracts with the Canadian Armed Forces and Coast Guard and validating its autonomous drone technology for government applications.
View raw filing on EDGAR →
8-K
Operational Other
confidence 65%
filed 2026-09-22
Item 1.01
CTT Pharmaceutical entered into a material definitive agreement. The specific nature of the agreement—whether a supply contract, licensing deal, partnership, or other operational arrangement—is not detailed in the Item 1.01 disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-22
The filing discloses completion of U.S. GoldMining's 2026 exploration drill program at its Whistler Gold-Copper Project in Alaska, with 7,493 meters drilled across 17 holes targeting high-priority porphyry centers. This is an operational milestone for an exploration-stage company advancing its primary asset, supported by a March 2026 PEA showing US$2.04 billion after-tax NPV and 33% IRR. While the disclosure is furnished under Item 7.01 (Regulation FD) rather than a dedicated 8-K item, the completion of a record drilling program and anticipated assay results represent material operational progress for a development-stage mining company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-22
Tonix announced a second major managed Medicare payer agreement for TONMYA® effective immediately, adding approximately 21 million Medicare lives (38% of U.S. Medicare beneficiaries) and bringing total commercial and government coverage to approximately 166 million covered lives (53% of U.S. population). This is a material operational and commercial milestone for the company's flagship product launch, reflecting significant progress in market access and patient reach, but does not fit the specific categories of M&A, debt issuance, earnings release, or other defined event types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-22
EX-99.1
This press release announces the expansion of TrainAlta's Warrior Training Program across 27 UFC GYM locations in a November 2026 launch cycle, representing approximately 29% growth in location count and described as "the largest launch in the partnership's history." While this is a significant operational and strategic milestone for the company's core business platform, it does not fit neatly into the specific event categories (it is not M&A, a material impairment, a covenant breach, or a discrete financial event like debt issuance). The disclosure is material because it demonstrates material business expansion and growth execution in the company's primary revenue-generating platform, which would affect a reasonable investor's assessment of the registrant's operational trajectory and market penetration strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-22
EX-99.1
This press release announces positive metallurgical testwork results from the University of Brighton demonstrating 73% rare earth recovery using in-situ recovery (ISR) methods at IMC's Itarantim Project. The disclosure describes a material operational and strategic development milestone—validation of a potentially lower-cost, lower-capital extraction pathway—that would affect investor assessment of the project's economic viability and development pathway. While not a discrete M&A event, executive change, or financial result, it represents a significant operational advancement for the company's principal project.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-22
Idaho Copper disclosed receipt of U.S. Forest Service approval for its Exploration Plan of Operations and 2026 annual operating plan at the CuMo copper-molybdenum project in Idaho. This is a material operational and regulatory milestone that clears the way for drilling and roadbuilding activities to commence after a decade of permitting work. The approval directly enables the company's planned exploration and drilling program, making it a significant operational event that would affect a reasonable investor's assessment of project advancement and execution risk.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-22
The filing discloses Beeline's launch of a "Rate Optimization Program" offering $3,000 lender credits on Bank Statement mortgages, coupled with commentary on Q3 2026 revenue trends and the company's strategic shift toward higher-margin Non-QM mortgage products. While the press release includes forward-looking statements about revenue growth and market opportunity, the core disclosure is a business initiative and product launch rather than a discrete financial event (earnings release, debt issuance, M&A), governance change, or material impairment. This is a material operational/strategic announcement affecting the company's business direction and competitive positioning in the mortgage lending market.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-22
Item 7.01
The disclosure announces favorable regulatory and coding outcomes for Lucid's EsoGuard and EsoCheck products: CMS Medicare Advisory Panel recommended maintaining the original gapfill payment basis, AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic cell collection, and CDC/NCHS ICD-10 Coordination Committee favorably received a proposal for a new diagnosis code. These advances directly expand reimbursement and billing pathways for the company's commercial-stage diagnostic products, representing material operational and commercial progress that would affect investor assessment of the company's market access and revenue potential.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-22
EX-99.1
This news release announces exploration results and regulatory approvals at Blue Moon's Springer tungsten project, including assay results from a historical core re-logging campaign (e.g., "7.00 m of 1.28% WO3"), completion of stockpile sampling (499 samples), and BLM approval to drill on public land. These are operational and strategic exploration milestones that advance the project's development and resource understanding, not a discrete financial event, M&A activity, or governance matter. The disclosure is material because it demonstrates progress on a material asset and provides investors with updated technical information about project potential.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-22
Item 8.01
TriSalus announced FDA 510(k) clearance for its TriNav Advance device on September 22, 2026, enabling commercialization of a new product in its PEDD portfolio. This is a material regulatory milestone and product launch event that would affect investor assessment of the company's commercial prospects and revenue potential, but it does not fit the specific named categories (earnings, M&A, impairment, litigation, etc.). The event is clearly operational—a regulatory approval and product expansion—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-22
Item 8.01
Vistagen announced preliminary positive data from the open-label extension of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder, demonstrating safety and efficacy improvements over four months. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate, affecting investor assessment of regulatory pathway and commercialization potential. While not a traditional earnings release or M&A event, the clinical data disclosure represents a significant operational/development milestone that would influence a reasonable investor's view of the company's prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-22
Item 7.01
ProPetro's PROPWR subsidiary has entered into long-term contracts to commit approximately 230 megawatts of power generation capacity to Targa Resources Corp., bringing total committed capacity to 510 MW. This represents a material operational and strategic development for the company's power services business line, demonstrating customer acquisition and capacity deployment in a growing market segment. While this is a significant business contract, it does not fit the specific categories of M&A activity, debt issuance, or other defined financial events—it is a material operational/commercial milestone for the PROPWR division.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-22
Item 7.01
The filing discloses the announcement of early access to Quantum Pilot, a new hardware-agnostic cloud-based software platform designed to help enterprises identify and develop quantum applications. This is a material product launch announcement that represents a significant operational and strategic development for Zapata Quantum, a pure-play quantum software company. While not fitting a specific named category (not M&A, not a financial event, not governance), the disclosure of a major new product offering is clearly operational and material to investors assessing the company's competitive positioning and growth prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-22
Item 8.01
Northwest Natural Holding Co announced settlement of a Texas general rate case for its SiEnergy Gas subsidiaries, providing for an $8.6 million annual revenue increase, a $343 million rate base, a 59.75% equity capital structure, and a 9.8% return on equity. This material regulatory milestone consolidates entities and establishes favorable terms affecting the subsidiary's future operations and profitability.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-22
EX-99.1
This press release announces NuRAN's first-of-its-kind pilot to integrate Starlink LEO satellite backhaul into its rural 4G infrastructure in Nigeria with partner Infratel. The disclosure is primarily operational and strategic—describing a new technology deployment and business-model evolution—rather than a discrete financial event (earnings, debt, M&A) or governance matter. The pilot is material because it represents a significant strategic initiative to unlock new revenue streams (edge AI, local compute, NuEnergy) and expand the company's addressable market across its 5,000+ contracted sites in Africa, directly affecting investor assessment of growth prospects and competitive positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-22
Item 8.01
Interparfums has entered into an exclusive, worldwide license agreement with PUMA for fragrance creation, development, production, and distribution through December 31, 2037. This is a material strategic partnership and licensing arrangement that expands the company's brand portfolio and revenue opportunities. While not a traditional M&A transaction, it represents a significant operational and commercial commitment that would affect a reasonable investor's assessment of the company's growth prospects and business strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-22
The disclosure announces positive Phase II topline data for leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation, including favorable safety and tolerability results and clinical improvements such as 26.4% mean spleen volume reduction. This is a material clinical development milestone for a drug candidate under regulatory review, but it does not fit the discrete event categories (not earnings, M&A, executive change, impairment, litigation, or debt-related). It is an operational/strategic advancement in the company's clinical pipeline that would affect a reasonable investor's assessment of the registrant's prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-22
EX-99.1
This exhibit is an Investor Day press release announcing On's strategic vision and mid-term financial targets through 2029, including entry into new sports categories (Football and Golf), the Premium Playbook framework, and a USD 1 billion share repurchase authorization. While it includes forward-looking financial guidance and a governance event (Lead Independent Director appointment), the primary substance is a strategic business announcement with operational and financial ambitions rather than a discrete material event fitting the standard taxonomy. The share repurchase authorization is capital allocation policy rather than an immediate issuance or distribution event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-22
Cadeler announced a memorandum of understanding with Vattenfall Vindkraft AB to collaborate on next-generation operations & maintenance (O&M) solutions for offshore wind, specifically focusing on Major Component Exchange (MCE) capabilities. This is a strategic partnership announcement that does not fit the discrete event categories (not an M&A transaction, not a contract award with defined revenue, not a regulatory milestone), but represents a material operational and strategic development for the company's Nexra O&M platform. The collaboration is material to investors as it signals expansion of Cadeler's service offerings and market positioning in the growing offshore wind aftermarket.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
Item 7.01
Deep Fission announced a collaboration with Youngquist Brothers to evaluate and test drilling and borehole-construction methods for its underground reactor deployment model. This is a material operational/strategic partnership that advances the company's core technology development toward commercial deployment targeted for 2027. While the collaboration itself is not a completed M&A transaction, it represents a significant operational milestone in the company's path to commercialization and would affect a reasonable investor's assessment of execution risk and technical feasibility.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
EX-99.1
This press release announces a three-year subscription agreement with Colonnade Insurance S.A. (owned by Fairfax Financial Holdings) for an integrated flood risk and property valuation solution. The disclosure emphasizes this as a strategic commercial contract that "advances Intermap's strategy to scale recurring insurance analytics solutions across global markets" with planned multi-country expansion from Czech Republic to Slovakia, Hungary, and broader Central and Eastern Europe by 2028. While not a discrete M&A transaction, this is a material operational and commercial milestone representing a significant recurring revenue contract with a major financial services entity, supporting the company's stated growth strategy in the insurance sector.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-21
Item 8.01
Alkermes disclosed positive Phase 1b clinical trial results for ALKS 7290, an investigational orexin 2 receptor agonist for ADHD, demonstrating clinically meaningful improvements in ADHD symptoms on validated scales (AISRS and CGI-S) and good tolerability. The company is advancing the program to Phase 2 trials, representing a material clinical development milestone that affects investor assessment of the company's pipeline value and strategic direction in neuroscience.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-21
Item 8.01
Cue Biopharma announced positive Phase 2 clinical trial results for CUE-221 in chronic spontaneous urticaria, with the primary endpoint met at all dose levels and a key secondary endpoint met at the highest dose, demonstrating a favorable safety profile. The company plans to advance to Phase 2b/3 registration-enabling study in CSU and Phase 2 in food allergy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-21
EX-99.1
This press release announces a significant technical milestone: MindWalk's successful production deployment of OpenFold3 on AMD Instinct MI325X GPUs via Vultr Kubernetes Engine, achieving approximately 5x faster antibody-antigen inference. The disclosure demonstrates ReefIQ's model-agnostic architecture and elastic compute capabilities, directly supporting the company's enterprise adoption strategy following ReefIQ's June 2026 launch. While not a discrete M&A, financing, or governance event, this operational and strategic validation of core platform capabilities—reducing deployment friction and operational costs for enterprise partners—is material to investors assessing MindWalk's ability to scale its Bio-Native AI platform and convert technical validation into contracted arrangements.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-21
Item 8.01
The disclosure announces the European Commission's grant of marketing authorization for two obicetrapib formulations (Ubeslo® and Evlarco®), representing the first worldwide regulatory approval of this drug candidate. This is a material operational and commercial milestone for a pharmaceutical company, triggering milestone payments in the "mid-teens of millions of euros" and establishing the foundation for commercialization in Europe through the Menarini partnership. While not a traditional M&A transaction or earnings release, this regulatory approval is a transformative operational event that would materially affect investor assessment of the company's pipeline and revenue prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
Item 7.01
This Item 7.01 disclosure furnishes a corporate presentation detailing Metagenomi's gene editing platform, lead program MGX-001 for hemophilia A, preclinical data, development roadmap, and pipeline expansion strategy. The presentation covers material operational and strategic information—including cash runway through Q4 2027, FDA pre-IND meeting completion in December 2025, planned Q4 2026 IND submission, and first-patient-dosed timeline in 2027—that would affect a reasonable investor's assessment of the company's clinical progress and capital adequacy. While the disclosure is operational and strategic rather than a specific event type (not M&A, not a restatement, not an impairment), it constitutes material disclosure of the company's therapeutic development status and near-term milestones.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
EX-99.1
This press release announces completion of the dewatering programme at Redwing Mine, the first milestone in a five-step restart pathway for the asset. The disclosure is operational in nature—it reports progress on a material capital project and mine restart initiative that directly affects the company's production capacity and strategic objectives. While not fitting a discrete event category like M&A or workforce reduction, the achievement of a major operational milestone ahead of schedule on a key asset restart is material to investors assessing the company's execution capability and path to production.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
EX-99.1
This press release announces completion of the last patient visit in the Phase 2a INFORM-MS clinical trial of intranasal foralumab for Secondary Progressive Multiple Sclerosis. The company expects to lock the database and announce topline data in October. This is a material clinical development milestone for a clinical-stage biotech company's lead candidate, affecting investor assessment of pipeline progress and near-term catalysts, but it is not a discrete event type (earnings, M&A, executive change, etc.) — it is an operational/clinical milestone best classified as operational_other.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
Item 8.01
The disclosure describes receipt of a statement of work (SOW) under a previously-disclosed Master Services Agreement with a national retailer, committing the Client to purchase and deploy 200 DUST-E autonomous cleaning robots over five years with ancillary services. This is a material operational/commercial milestone—a significant product order from a major customer—but does not fit the specific categories of M&A, debt, equity issuance, or other named event types. It is clearly operational in nature and material to a reasonable investor assessing the company's revenue prospects and customer base.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
Evolution Metals & Technologies Corp. announced its inclusion in the Russell 3000® and Russell 2000® indexes effective September 21, 2026, following FTSE Russell's third-quarter IPO additions process. The filing emphasizes that approximately $12.2 trillion in assets are benchmarked to these indexes, positioning the company for increased institutional visibility and liquidity. While index inclusion is primarily a capital-markets recognition event rather than an operational or financial transaction, it is material to investors as it affects market accessibility and shareholder base composition. This does not fit neatly into earnings, M&A, debt, or other specific categories, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
Item 8.01
Faraday Future announced the launch of nine new EAI (Embodied AI) robot device configurations and four industry productivity solutions at its 919 event on September 19, 2026. The disclosure details new product lines (FF All-New Futurist, FF Master Mini, FX Aegis series) with specific pricing and technical specifications, along with a new "6+1" direct sales and robot-sharing rental network. This is a material operational and strategic business event—a significant product launch and go-to-market initiative—that does not fit the specific categories of earnings release, M&A, or other named event types. The materiality is supported by the company's emphasis on completing its "EAI Robot World 2.0" ecosystem and establishing new sales channels, which are core to its business strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
The filing discloses entry into a material definitive agreement (Item 1.01) for the purchase of 32 GPU server units from Compal Electronics for approximately $18.8 million. While this is a capital equipment purchase agreement, it does not fit neatly into the standard financial categories (debt_issuance, ma_activity, etc.). The transaction represents a significant operational and strategic commitment to develop the Company's artificial intelligence computing infrastructure business, making it an operational event rather than a financial obligation or M&A activity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
Item 8.01
Matternet announced that its common stock has qualified to trade on the OTCQB Venture Market and commenced trading under ticker "MTTN" on September 21, 2026. This is a listing event that affects the registrant's public trading status and accessibility to investors, making it material. While not a delisting risk or change of listing venue per se, it represents a significant operational milestone in the company's public market presence that would affect investor assessment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
EX-99.1
This news release discloses material progress on the Apollo deposit's processing flowsheet and metallurgical test results, advancing toward a planned 2027 licensing submission in Colombia. The disclosure includes strong metallurgical recoveries (95% gold, 92% silver, 85% copper) and a dual-route processing strategy with defined copper and tungsten sub-domains. While not a discrete M&A, financing, or governance event, this represents a material operational and strategic milestone for an exploration-stage company advancing a major mineral project toward development, directly affecting investor assessment of the project's viability and timeline.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-21
EX-99.1
DeFi Technologies' subsidiary Valour has launched a new business line (Valour Funds SPC) and introduced its first hedge fund product (Smart Crypto Fund SP). This represents a material expansion of the company's investment platform beyond its existing exchange-traded products into actively managed hedge fund strategies, combining Valour's digital asset infrastructure with Neuronomics' AI-driven systematic investment expertise. While this is a strategic business development rather than a discrete M&A transaction, earnings event, or governance matter, it materially expands the registrant's operational scope and revenue-generating capabilities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-21
Item 7.01
The disclosure announces a major regulatory milestone: the U.S. Army Corps of Engineers has published a Notice of Intent to prepare an Environmental Impact Statement for Trilogy's flagship Arctic Project. This formally initiates the NEPA environmental review process and launches the public scoping phase, marking progress on a coordinated federal permitting schedule targeting a Record of Decision in September 2028. This is a material operational/strategic event for a mining exploration and development company, as it advances a critical minerals project through the federal permitting process, but it does not fit the specific categories of M&A activity, material impairment, litigation, or other named event types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-21
Petrobras announces Board approval to participate in a new Brazilian government economic subsidy program (Provisional Measure No. 1,391/2026) providing R$1.00 per liter of diesel fuel for 30 days, cumulative with an existing R$1.12/liter subsidy. This is a material operational and strategic decision affecting the company's commercial positioning and profitability, though it is neither a discrete M&A event, workforce action, nor financial obligation in the traditional sense—it is a government subsidy arrangement that impacts pricing strategy and margins.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-21
EX-99.1
The exhibit is a press release disclosing operational milestones (completion of fracture stimulation on three Clifton Mack wells, drilling completion of the Lovina 8-5-1HF well in the False Caney bench) and capital allocation decisions (renewal of a normal course issuer bid to repurchase up to 1.8M shares, ~5% of outstanding). The operational updates describe material well development and production expectations; the share buyback renewal is a routine capital allocation decision. While the buyback is administrative, the well completions and new production horizon testing are material operational events affecting future cash flow and reserve conversion.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
EX-99.1
Almonty announced receipt of final mining facility inspection certificates (issued September 17, 2026) authorizing commercial operation of its Sangdong processing plant and crushing facilities in South Korea. This is a material operational milestone enabling the company to commence commercial production and sales of tungsten concentrate, with over 90% of Phase I production already contracted under a 21-year offtake agreement with Global Tungsten & Powders LLC. The certification represents the transition from construction and trial operation to commercial production, directly enabling revenue generation from a flagship asset.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-21
EX-99.1
This press release announces the successful commercialization of OpsWiz, Vantage's proprietary cloud-based operational platform, and the securing of its first external customer, Felcor Petroleum. The announcement represents a material operational and strategic milestone—the transition of an internal tool to a revenue-generating product line that diversifies the company beyond traditional shipbroking. CEO D'Rozario explicitly characterizes this as "a significant milestone" and notes it demonstrates "the platform's potential beyond our internal shipbroking operations" and is "an important part of our business as we continue to diversify." This is a material operational event that would affect a reasonable investor's assessment of the company's growth strategy and revenue diversification, but it does not fit a more specific category (it is neither a discrete M&A transaction, a material contract disclosure, nor a financial result).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
The filing discloses a material operational and strategic development: AMC Robotics' buildout of a manufacturing facility in Vietnam targeting $30 million in annual production capacity, with Phase 1 commissioning expected by end of 2026 and trial production in early 2027. This represents a significant capital investment and operational milestone for scaling production of the company's AI-powered robotics solutions. While disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated operational Item, the substance is a material manufacturing and supply-chain diversification initiative that would affect a reasonable investor's assessment of the company's growth trajectory and operational capabilities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-21
The filing discloses an operational update on the Company's cryptocurrency holdings and treasury strategy, including ETH accumulation milestones (5.98 million tokens, 4.9% of total ETH supply), staking operations (5.067 million staked ETH generating projected $357 million annualized revenues), and total crypto and cash holdings of $17.1 billion. While the press release contains forward-looking statements about market conditions and strategic goals, the core disclosure centers on the Company's operational achievements and current asset position rather than a specific financial event (earnings, debt, impairment) or governance matter. This is material to investors assessing the registrant's digital asset strategy and operational performance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-21
The filing discloses a technical update on the Hycroft Mine's advancement toward production, including underground development planning at Brimstone and Vortex, metallurgical test work on roasting and pressure oxidation, and assessment of heap leach restart operations. The company also announces a refreshed brand identity and updated corporate presentation. This is an operational/strategic disclosure about project development progress and capital allocation decisions, not a specific named event type (no M&A, impairment, covenant breach, or other terminal/financial trigger). Item 7.01 (Regulation FD Disclosure) is the appropriate vehicle for such operational updates.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
Item 7.01
Sunshine Silver announced a 60% expansion of its Silver Valley mineral rights position (from ~24,000 to ~38,000 acres) and initiation of a multi-year, 45,000-meter district-scale exploration program targeting three drill-ready areas. This is a material operational and strategic development—a significant expansion of the company's exploration footprint and resource base—but does not fit the specific categories of M&A activity, material impairment, or other named event types. The disclosure is operational in nature, relating to exploration strategy and land position expansion rather than financial results, executive changes, or accounting matters.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-21
Item 8.01
Strive announced a bitcoin purchase of 1,355 BTC at ~$79,475 per bitcoin during September 14-18, 2026, along with updated holdings of cash, bitcoin, and equity securities. This is a material operational/strategic disclosure of the company's treasury management and bitcoin accumulation strategy, which is central to Strive's business model. While not fitting a specific named event type, it clearly represents a material operational event affecting the company's asset composition and financial position.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
This press release announces positive drilling results from Guardian Metal's Tempiute tungsten project, including broad mineralization intersections (notably 92.0m @ 0.34% WO3) and a decision to commence underground mine rehabilitation. The disclosure is primarily operational—reporting exploration progress, drilling data, and a strategic decision to accelerate development activities—rather than a discrete financial event, M&A transaction, or governance matter. While exploration-stage companies' drilling results can be material to investors assessing project viability and advancement, this is best classified as an operational milestone rather than a periodic financial report or other event type.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
The 6-K discloses a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Enhertu (trastuzumab deruxtecan) in the EU as adjuvant treatment for HER2-positive early breast cancer with residual disease. This is a material regulatory milestone for a key oncology product—the DESTINY-Breast05 trial showed 53% risk reduction in invasive disease recurrence or death versus the current standard of care (T-DM1). While not a discrete M&A, financial, or governance event, this regulatory advancement represents a significant operational and commercial milestone that would affect a reasonable investor's assessment of the company's pipeline and market opportunities.
View raw filing on EDGAR →